Indinavir-Induced Retinoid-Like Effects

Since 1998, many cases of antiretroviral therapy-related paronychia of the toes or fingers and ingrown toenails have been reported. Most of them were related to indinavir. Other indinavir-induced mucocutaneous disorders resembling the adverse effects of systemic retinoid therapy have also been reported. Although there is some uncertainty in the literature regarding a cause-effect relationship, results of several epidemiological and in vitro studies, together with cumulated clinical experience leave no doubt that indinavir causes a retinoid-like effect and nail alterations. Indeed, indinavir is the only antiretroviral drug that produces these disorders, although ritonavir may enhance indinavir-induced retinoid-like effects through pharmacokinetic interactions leading to increased plasma indinavir concentrations.Approximately 30% of patients receiving indinavir show two or more retinoid-like manifestations and 4–9% develop paronychia. These adverse effects are not related to other epidemiological variables such as the patient’s sex, age or other risk factors or immune status. They seem to be exposure dependent and, therefore, largely dose-dependent.Chronic paronychia is considered generally to be caused by contact irritants and candidal infection. Nevertheless, indinavir is currently the most frequent cause of chronic or recurrent paronychia in HIV-infected patients. In addition, retinoid-like manifestations such as cutaneous xerosis and cheilitis are frequent mucocutaneous adverse effects related to indinavir.The exact mechanism of indinavir-induced retinoid-like effects is unclear. Hypotheses for pathogenesis include interference with retinoid metabolism by enhancing the retinoic acid signalling pathway, or by increasing retinoic acid synthesis, or by reducing cytochrome P450-mediated retinoic acid oxidative metabolism.Replacement of therapy by an antiretroviral regimen not containing indinavir, while retaining other protease inhibitors and lamivudine, resolves retinoid-like manifestations without recurrences.

[1]  R. Scher,et al.  Indinavir-related recurrent paronychia and ingrown toenails. , 1999, Cutis.

[2]  E. Furfine,et al.  Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. , 2000, Biochemical pharmacology.

[3]  S. Mauss HIV-associated lipodystrophy syndrome. , 2000, AIDS.

[4]  J. Viel,et al.  Ingrown toenail and indinavir: case-control study demonstrates strong relationship. , 1999, AIDS (London).

[5]  Guoxiong Xu,et al.  Cellular retinol-binding protein-1 is transiently expressed in granulation tissue fibroblasts and differentially expressed in fibroblasts cultured from different organs. , 1997, The American journal of pathology.

[6]  C. Bouchard,et al.  Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. , 1998, The New England journal of medicine.

[7]  R. Platt,et al.  Paronychia in association with indinavir treatment. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Prichard Jg,et al.  Paronychia of the great toes associated with protease inhibitors. , 1999 .

[9]  C. Scully,et al.  Orofacial effects of antiretroviral therapies. , 2001, Oral diseases.

[10]  D. Back,et al.  Principles and practice of HIV‐protease inhibitor pharmacoenhancement , 2001, HIV medicine.

[11]  I. Salvary,et al.  Indinavir use: associated reversible hair loss and mood disturbance , 2000, International Journal of STD and AIDS.

[12]  Tosti,et al.  Paronychia associated with antiretroviral therapy , 1999, The British journal of dermatology.

[13]  J. del Pozo,et al.  Protease inhibitor-related paronychia, ingrown toenails, desquamative cheilitis and cutaneous xerosis. , 2000, AIDS.

[14]  M. Cusini,et al.  Lamivudine-induced paronychia , 1998, The Lancet.

[15]  A. d’Arminio Monforte,et al.  Indinavir-related alopecia. , 1998, AIDS.

[16]  Nancy L. Deutsch,et al.  Suicide, depression, and isotretinoin: is there a causal link? , 2001, Journal of the American Academy of Dermatology.

[17]  F. Bergmann,et al.  Drug interaction of isotretinoin and protease inhibitors: support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy? , 1999, AIDS.

[18]  D. Devost,et al.  HIV-protease inhibitors alter retinoic acid synthesis , 2001, AIDS.

[19]  B. Berman,et al.  HIV and AIDS in inpatient dermatology. Approach to the consultation. , 2000, Dermatologic clinics.

[20]  I. Panse,et al.  Lipodystrophy associated with protease inhibitors , 2000, The British journal of dermatology.

[21]  S. Matheron,et al.  Alopecia associated with indinavir therapy. , 1999, The New England journal of medicine.

[22]  E. Bottieau,et al.  Curly hair and lipodystrophy as a result of highly active antiretroviral treatment? , 2000, Archives of dermatology.

[23]  R. Baran Etretinate and the nails (study of 130 cases) possible mechanisms of some side‐effects , 1986, Clinical and experimental dermatology.

[24]  V. Lorenzo-Zúñiga,et al.  Generalized hair loss induced by indinavir plus ritonavir therapy. , 2002, AIDS (London).

[25]  D. Hawkins,et al.  Cheilitis in association with indinavir , 2000, Sexually Transmitted Infections.

[26]  N. Swanson,et al.  Retinoid therapy is associated with excess granulation tissue responses. , 1983, Journal of the American Academy of Dermatology.

[27]  J. Maleville,et al.  Retinoid dermatitis mimicking "eczéma craquelé". , 1985, Acta dermato-venereologica.

[28]  G. Russo,et al.  Cutaneous manifestations of antiretroviral therapy. , 2002, Journal of the American Academy of Dermatology.

[29]  C. R. Daniel,et al.  The spectrum of nail disease in patients with human immunodeficiency virus infection. , 1992, Journal of the American Academy of Dermatology.

[30]  M. Turner,et al.  Alopecia universalis and Graves' disease in the setting of immune restoration after highly active antiretroviral therapy. , 2001, AIDS.

[31]  C. Bunker,et al.  Isotretinoin and curly hair , 1990, Clinical and experimental dermatology.

[32]  A. Boschini,et al.  Cutaneous side effects induced by indinavir. , 1998, European journal of dermatology : EJD.

[33]  A. Antinori,et al.  Self-Reported Nonadherence with Antiretroviral Drugs Predicts Persistent Condition , 2001, HIV clinical trials.

[34]  P. Hull,et al.  Isotretinoin Use in Acne: Prospective Evaluation of Adverse Events , 2000, Journal of cutaneous medicine and surgery.

[35]  J. Sass,et al.  Paronychia with Pyogenic Granuloma in a Child Treated with Indinavir: The Retinoid-Mediated Side Effect Theory Revisited , 2000, Dermatology.

[36]  S. Szabo,et al.  Recurrent Ingrown Toenails Secondary to Indinavir/Ritonavir Combination Therapy , 2001, The Annals of pharmacotherapy.

[37]  D. Cooper,et al.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.

[38]  L. Gerber,et al.  Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. , 1986, The New England journal of medicine.

[39]  E. Dauden,et al.  Paronychia and excess granulation tissue of the toes and finger in a patient treated with indinavir , 2000, The British journal of dermatology.

[40]  M. Sprangers,et al.  Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. , 2001, Archives of internal medicine.

[41]  B. Piraccini,et al.  Drug-Induced Nail Disorders , 1999, Drug safety.

[42]  G. Garber,et al.  Acute monoarthritis complicating therapy with indinavir. , 2000, AIDS.

[43]  L. Amado,et al.  Paroniquia en pacientes infectados por el VIH tratados con indinavir , 2001 .

[44]  J. Schapiro,et al.  Drug‐induced and traumatic nail problems in the haemophilias , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.